Drug Trial Radar · NCT07142811
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Aug 5, 2025
Primary completion
Mar 2029
Study completion Jul 2030
Sponsor
- Lead sponsor
- Vir Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection
Conditions
- Viral Hepatitis
Interventions
TobevibartDrug
Tobevibart administered by subcutaneous injection
ElebsiranDrug
Elebsiran administered by subcutaneous injection
BulevirtideDrug
Bulevirtide administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 48Time frame: Week 48
- HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) 24 weeks after end of treatmentTime frame: 24 Weeks after End of Treatment
- Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 48Time frame: Week 48
Locations
27 sites in 11 countries. Site status is shown where the registry gives one.
Investigative Site
Brussels, Belgium
Investigative Site
Brussels, Belgium
Investigative Site
Edegem, Belgium
Investigative Site
Sofia, Bulgaria
Investigative Site
Sofia, Bulgaria
Investigative Site
Stara Zagora, Bulgaria
Investigative Site
Clichy, France
Investigative Site
Créteil, France
Investigative Site
Limoges, France
Investigative Site
Rennes, France
Investigative Site
Toulouse, France
Investigative Site
Hanover, Germany
Investigative Site
Chisinau, Moldova
Investigative Site
Amsterdam, Netherlands
Investigative Site
Rotterdam, Netherlands
Investigative Site
Karachi, Pakistan
Investigative Site
Karachi, Pakistan
Investigative Site
Lahore, Pakistan
Investigative Site
Rawalpindi, Pakistan
Investigative Site
Bucharest, Romania
Investigative Site
Barcelona, Spain
Investigative Site
Madrid, Spain
Investigative
Valencia, Spain
Investigative Site
Kyiv, Ukraine
Investigative Site
London, United Kingdom
Investigative Site
London, United Kingdom
Investigative Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.